Business Context and Reporting Period
This Form 8-K Current Report was filed by BioRestorative Therapies, Inc. on March 18, 2021. The registrant is an emerging growth company incorporated in Delaware. The filing primarily addresses corporate governance changes, the adoption of a new stock incentive plan, and the execution of employment agreements with key executives.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational events rather than periodic financial performance data.
Material Changes and Corporate Actions
- Board Election: Nickolay Kukekov was elected as a director on March 18, 2021.
- Stock Incentive Plan: The Board adopted the 2021 Stock Incentive Plan, authorizing the issuance of 4,700,000,000 shares of common stock for options, restricted stock units (RSUs), restricted stock, and stock appreciation rights.
- Executive Employment Agreements: New five-year agreements (ending March 18, 2026) were signed with:
- Lance Alstodt (President, CEO, Chairman): Initial annual salary of $250,000 with $50,000 annual increases and a potential $150,000 performance increase. Granted options for 1,173,917,974 shares and 586,958,987 RSUs.
- Francisco Silva (VP, Research and Development): Initial annual salary of $225,000 with $50,000 annual increases and a potential $150,000 performance increase. Granted options for 1,173,917,974 shares and 586,958,987 RSUs.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, forward-looking outlook statements, or a discussion of general business risks. The primary contingency noted is the performance-based salary increases for the executives, which are contingent on meeting certain goals not detailed in this summary.
Investor Verification Checklist
- Verify the total authorized share count of the company to assess the dilution impact of the 4.7 billion shares authorized under the new Stock Incentive Plan.
- Review the specific performance goals required for the $150,000 salary increases for Mr. Alstodt and Mr. Silva.
- Examine the full text of the employment agreements (Exhibits 99.2 and 99.3) for termination clauses and severance provisions.
- Confirm the vesting schedules for the massive option and RSU grants (over 1.7 billion shares total per executive) detailed in Exhibits 99.4 through 99.7.